NASDAQ: MBIOMustang Bio Inc Stock
$0.65+0.02 (+3.17%)
Updated Jul 20, 2026
MBIO Price
$0.65
Fair Value Price
N/A
Market Cap
$4.94M
52 Week Low
$0.53
52 Week High
$2.12
P/E
-1.39x
P/B
0.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$2.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.93
Operating Cash Flow
-$5M
Beta
1.47
Next Earnings
Aug 14, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MBIO Overview
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MBIO's potential to beat the market
- MBIO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MBIO
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $243.47 | A | |
| $11.15 | A | |
| $8.60 | A |
Be the first to know about important MBIO news, forecast changes, insider trades & much more!
MBIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MBIO is good value based on its book value relative to its share price (0.57x), compared to the US Biotechnology industry average (5.33x)
P/B vs Industry Valuation
MBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MBIO due diligence checks available for Premium users.
Valuation
MBIO fair value
Fair Value of MBIO stock based on Discounted Cash Flow (DCF)
Price
$0.65
Fair Value
$0.35
Overvalued by
84.77%
MBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.39x
Industry
21.5x
Market
11.71x
MBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
5.33x
MBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MBIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$955.0k
Profit Margin
0%
MBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$16.6M
Liabilities
$8.0M
Debt to equity
0.93
MBIO's short-term assets ($16.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBIO's short-term assets ($16.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
$0.0
Financing
$0.0
MBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBIO vs Biotech Stocks
Mustang Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.